Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fully agree with that sentiment, and all too aware of your previous comment about our own shelf life realities. I saw an interesting piece on MoneyWeek about AIM shares being treated more kindly on inheritance tax. Perhaps the next generation will view this as a wise choice, but don't think I'll hold my breath on that one.
Ringing lots of bells there alf. FWIW I used to work with the eponymous Stephen Nigel in a previous life when he was one of BP Nutrition's young thrusters out of Northwich. Interesting character, I'll say no more than that.
I guess the one thing we can all agree on is a hope that our long-term loyalty to this company will eventually be rewarded handsomely. I'm hoping to be here when it happens. K
I think you are missing my point there Krusty. Every one of us who put money in the AIM listed shares know that the risk is always present. There are many interpretations of the events of 2009. For sure a poster on here had an enthusiastic following of newbies, and perhaps CB was one of them. The original suggestion, that acquiring EFSA approval would unlock the potential, was a fair one, indeed the word transformational was stated. As with all things EU, the pompous authority claimed wasn't matched by the reality, having the approval did little to influence brands at a time that the largest companies were highly risk averse due to the market crash. We saw the first "know of no reason" RNS after the rapid rise. A market cap of £100m was hard to justify, and anyone who bought at that time wasn't too savvy. However, that warning did little to dent the over heating. So, we then had the infamous sell by the CEO, which did deflate many, and rightly so. Was that deliberate, did advisors decide it was the only way to restore some reality? That's possible IMHO but I've never discussed it with anyone there so it is only my speculation. The company spent raised funds on acquisition, I believe they had the business model that rising revenues from Fruitflow would fund the rapid expansion of the sports nutrition arm. When it became clear that insti investors were willing to fund the SiS business model, it was floated off and that's just what happened. Fruitflow continued to see brands launching products world wide, without very much of the revenue coming the way of the IP holder. We all knew that the Alliance deal was secret, many people left due to lack of transparency, a fair decision, and some remained trying to judge when, and how much, to pay for further holdings. Enter the group of backers who have supported further fund raisings. Some swore that they would not throw more more funds in, their choice. Others took encouragement from the backing of the rich lads, I'm only one. I don't think it's bragging, we all stand or fall on our own choices. I've had losses in other places, mainly resources, but I don't lurk on those boards trying to piddle on other's strawberry patch.
Each to their own choices, but moaning endlessly about them isn't on IMHO
I think colbalt is just articulating the frustration many long-term shareholders feel with the share performance over many, many years. Alf brags about having a better average than many but I don't remember the company advising people to stay away when the price was 7p - just the opposite! Like many, I remain here because of the science, and in the belief that, sooner or later, the value of that science will be realised. You have to admit though, it's been a long, long time coming and no sign of it emerging any time soon. We all have a shelf-life, after all...
Showing increasing potential;Blinking hope so after 12 years!!!
Connection?
There has been a lot of studies regarding the Role of Autophagy in Covid-19.
https://www.google.co.uk/search?q=%22Autophagy+Covid-19%22&sxsrf=ALeKk01ayyZfLrkAhIe4K9TUXaXmBgvY9g%3A1627846054802&ei=pvUGYdy-MMmJ1fAP8JmjwA0&oq=%22Autophagy+Covid-19%22&gs_lcp=Cgdnd3Mtd2l6EAMyBggAEAcQHjoHCAAQRxCwAzoICAAQCBAHEB5KBAhBGABQnYoCWK6SAmCTmAJoAXACeACAAfQBiAHtA5IBBTMuMC4xmAEAoAEByAEIwAEB&sclient=gws-wiz&ved=0ahUKEwjcqeGOx5DyAhXJRBUIHfDMCNgQ4dUDCA4&uact=5
This study says "Results: It was revealed that autophagy has an important role in the manifestation of COVID-19 respiratory complications Conclusions: Autophagy is triggered by SARS-CoV2 virus for its replication and autophagy inhibitory treatments might be considered promising therapeutics."
https://www.researchgate.net/publication/340513984_The_Role_of_Autophagy_in_Respiratory_Complications_of_COVID-19
Now why would the Chinese have been doing this study
"Fruitflow,a Water-soluble Tomato Extract,Regulates Platelet Oxidative Damage via Autophagy in Vitro"
"Conclusion- Fruitflow can significantly reduce the H_(2)O_(2)-induced platelet oxidative damage by promoting autophagy in vitro."
http://222.198.130.40:81/Qikan/Article/Detail?id=7104674524&from=Qikan_Search_Index
CB, if you are upset then ring IF and put your frustrations to him. He may not be able to answer all your questions but at least you will got it off your chest. You have not been happy for years. Don't forget we give DSM the chance to get us a major or global. iF is the one who has given us a great chance with bi-health
Kievsky, I'm not too keen on the idea of being told to "sell and move on" if criticising a stock which is underperforming. I have made the mistake of being far too complacent with PXS over the last few years and was, at one time, a cheerleader for the company. I hope the Chinese venture eventually pays off (bearing in mind they are the toughest business cookies in the world) but I think the UK development side of the business has been very unsatisfactory and possibly at saturation point for the middle class worried well who are the main consumers (IMO). My gut simply tells me that the moment has passed. We could debate for weeks about why but it is a combination of many things. Good luck.
The continual flow of information posted by gixer and others can only confirm that Fruitflow, far from being dead, is showing increasing potential. Who could have predicted ten years ago that, during a global pandemic, Fruitflow was being studied for it's efficacy in dealing with the worst aspect of the virus, aggravated platelets.
The perpetual critic is viewing things through the prism of his own disastrous choices to buy and sell when he did, failing to appreciate that others are in a far more positive place due to different investment decisions. Anyone normal would have moved on, but this character is aching for the company to fail for his own bitter reasons. Bad manners.
gixer. I do think that you're so close to this share that you failed to grasp the sentiments in my posting. When I say "brought to the table" I mean what shareholder value has she brought since being appointed to the BOD? She should be the face and voice of the company ( At least a google search will reveal a few images unlike her boss!!) Missing the boat!? Look at the charts, the accounts, the current SP and complete lack of progress updates or any other news. The company makes enough money to pay the salaries. This after 10 years. Sorry about my mistake on the price per tablet. That should read 50p per pop. Still a lot for Joe Public. All the best.
Apologies for putting " Dietary antiplatelets: a new perspective on the health benefits of the water-soluble tomato concentrate Fruitflow®" in twice under Dr Niamh O'Kennedy maybe I should have only included it once or made it clear that one was a preprint and the other a review paper.
For those interested, this is a good site to look for Preprints, Reviews and Research articles by using a simple keyword search like Fruitflow.
https://europepmc.org/search?query=fruitflow
Sell what you have left and move on then. Everyone agrees it's taken miles longer than we all thought it would. No point moaning about it. Will still happen but we have to be paitent
Hi colbaltblue,
"Remember Dr Hilary Jones endorsing it? Others have come and gone"
Yes, But just like BHF these Doctors don't do anything for free.
"What exactly has Dr Niamh O'Kennedy brought to the table?"
Dietary Antiplatelets: A New Perspective on the Health Benefits of the Water-Soluble Tomato Concentrate Fruitflow®
Evaluation of the Equivalence of Different Intakes of Fruitflow® in Affecting Platelet Aggregation and Thrombin Generation Capacity in a Randomized, Pilot Study in Male Subjects
Dietary antiplatelets: a new perspective on the health benefits of the water-soluble tomato concentrate Fruitflow®
Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow® be used as an antiplatelet regime?
The above is some of what she has brought to the table this year.
"Why isn't she presenting?"
https://register.gotowebinar.com/register/4006498734757301774?source=MPS
As you can see from the link above, she does but if the likes of AFC want the inventor of FF then Duttaroy is the man.
Can I say that if you can only find Fruitflow at £1 a tablet then you are looking in the wrong places.
Can I also ask what boat has PXS comprehensively missed? and why the sp shows its to late?
CV disease, Covid-19, platelet aggregation, pollution, inflammation caused by sport & exercise, blood pressure etc. etc.
I am not aware of a cure for all or any of the above.
CB
The spelling mistakes in the Prof's recent presentation to me shows no one is reviewing his presentations e.g. 1:39:39, difeffernt, 1:27:13 redcution. Very shoddy. Niamh should be reviewing everything that is going out from DSM etc. concerning FF. She obviously isn't.
Let's not forget the Prof has set up a rival company that is promoting kiwi's impact on platelets. He needs to be managed better by PXS.
W$
Colbalt
I agree with most of what you are saying. Unfortunately lots of aim companies have excellent products with potential but well below par management who like the status quo.
Kievsky, you know FF works and I know it works. Problem is, it's simply not on the radar of the people that should know about it. Remember Dr Hilary Jones endorsing it? Others have come and gone. What exactly has Dr Niamh O'Kennedy brought to the table? Why isn't she presenting? BHF have never been interested because there's nothing in it for them. Joe Public can't afford it at £1 a tablet. The average GP has never heard of it. My Cardiologist had no comment on its effectiveness. The Chinese are taking forever and it's a decade since Sirco appeared and then disappeared from the supermarkets because nobody was buying it and supplies were unreliable. DSM a sleeping giant and FF possibly not the jewel in the crown anymore. IF, probably not the man for the job. Gixer's still doing his best but the company has been a lesson in comprehensively missing the boat. The market thinks so and the SP proves that it's too late.
I wonder if this throws up the prospect of further research funding?
Especially as FF saves lives. But Ff and coved-19 seems to be getting some traction
Yes nothing is free with them. And the supposedly to help people with heart problems. I am sure provexis would make a donation if they promoted our product
Cheers wellsite, organisations like the BHF don't do favours. Unfortunately everything has a price.
Gixer
nice find, I had noted FF cozying up to BHF and wondered why, as they have never done us any favours. Page 60 listing engaged organizations unfortunately does not list PXS - BHF listed twice !!
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000030/life-sciences-vision.pdf
That said, I can picture Boris standing outside #10 boasting that UK scientists have found that the humble tomato could help win the battle against CV.
Found this study re - Age, Medication Use Predict Severe COVID-19 in Diabetes
"Two other types of drugs were linked to a lower risk for severe COVID-19 — blood-pressure-lowering ACE inhibitors (25% lower risk) and cholesterol-lowering statins (34% lower risk)"
https://www.diabetesselfmanagement.com/news-research/2021/07/02/age-medication-use-predict-severe-covid-19-in-diabetes/
The next few months are gonna be very interesting
W?
Great job!!!!!!! A very generous assessment.
That wasn't the case around a year ago, for sure.
From the annual report.
"Ian has previously
divided his working time
between the UK and
Australia; in January
2020 Ian returned to live
full time in the UK."
I would assume his family have been here for a while as well.
Yes Agree. Very insensitive. He is doing a great job IMO and seems Mr Lucas agrees